The Initial Clinical Presentation of Spinocerebellar Ataxias Type 1, 2, 3, and 6 (P6.393)

Lan Luo,Jie Wang,Karla P. Figueroa,Stefan M. Pulst,Susan Perlman,George Wilmot,Christopher M. Gómez,Jeremy D. Schmahmann,Henry L. Paulson,Vikram G. Shakkottai,Sarah H. Ying,Theresa Zesiewicz,Khalaf Bushara,Michael D. Geschwind,Guangbin Xia,S. H. Subramony,Tetsuo Ashizawa,Sheng‐Han Kuo
DOI: https://doi.org/10.1212/wnl.86.16_supplement.p6.393
IF: 9.9
2016-01-01
Neurology
Abstract:Objective: To characterize the initial clinical presentation of spinocerebellar ataxias (SCA) type 1, 2, 3, and 6. Background: The SCAs are a group of genetically and clinically diverse neurodegenerative diseases and the understanding of initial clinical presentation of each SCA type will help pinpoint the clinical diagnosis. Methods: The Clinical Research Consortium for Spinocerebellar Ataxias (CRC-SCA) enrolled 317 participants with SCA 1, 2, 3 and 6 from 12 medical centers in the United States. The initial presentation to ataxia specialist was recorded, including age of onset of any gait, speech, vision, and hand abnormalities. Since the majority of patients had gait abnormality as the first symptom, we divided SCA patients into two groups: gait onset group or non-gait onset group. We compared the number of pathological CAG repeats and the age of disease onset between the gait onset group and the non-gait onset group using t-test or the Wilcoxon Mann-Whitney test. Results: The majority of SCA patients had gait problems initially and the percentage of these patients was similar across different types of SCAs (92.3[percnt] in SCA1, 87.0[percnt] in SCA2, 87.5[percnt] in SCA3, and 83.8[percnt] in SCA6, p= 0.59). The pathological CAG repeat expansions were similar between gait onset group and non-gait onset group in all four types of SCA patients. In addition, the disease onset for non-gait group in SCA2 patients was 9 years earlier than their counterpart (non-gait onset group 28.2 ± 14.8 years old vs. gait onset 37.2 ± 11.4 years old, p= 0.039). We did not observe any differences in disease onset between gait onset group and non-gait onset group in SCA1, 3, and 6. Conclusions: Gait abnormality is the most common initial presentation of SCAs. Interestingly, SCA2 patients with non-gait onset tend to have a younger disease onset, which might represent a subtype of SCA2. Disclosure: Dr. Luo has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Figueroa has nothing to disclose. Dr. Pulst has received personal compensation for activities with Ataxion Therapeutics and Roche Pharmaceuticals as a consultant. Dr. Pulst has received personal compensation in an editorial capacity for AAN Neurology: Genetics. Dr. Pulst has received (roy Dr. Perlman has received research support from Santhera Pharmaceuticals. Dr. Wilmot has nothing to disclose. Dr. Gomez has nothing to disclose. Dr. Schmahmann has received license fees payments from Massachusetts General Hospital. Dr. Paulson has received personal compensation for activities with Shire Human Genetic Therapy. Dr. Shakkottai has nothing to disclose. Dr. Ying has nothing to disclose. Dr Zesiewicz has received research support from FARA. Dr. Bushara has nothing to disclose. Dr. Geschwind has received personal compensation for activities with Best Doctors, Advanced Medical, Guidepoint Global, Gerson-Lehrman Group, and Quest Diagnostics. Dr. Geschwind has received research support from NIH/NIA, the Tau Consortium, Michael J. H Dr. Xia has nothing to disclose. Dr. Subramony has received research support from ISIS Pharmaceuticals, REATA Pharmaceuticals and Horizon Pharmaceuticals. Dr. Ashizawa has received royalty payments from Baylor College of Medicine. Dr. Kuo has nothing to disclose.
What problem does this paper attempt to address?